Pai, Nagesh
Acar, Mustafa
Juneja, Prabhjot
Kouhkamari, Mahsa Hosseini
Siva, Sinthuja
Mullan, Judy
Funding for this research was provided by:
Janssen-Cilag Pty Ltd
Article History
Received: 25 August 2021
Accepted: 28 January 2022
First Online: 12 February 2022
Declarations
:
: The Australian Government Department of Health provides access to the PBS dataset to suppliers for studies approved by the Australian Government Department of Human Services External Request Evaluation Committee. Only deidentified data are available for a subset of 10% of patients. All requests need to answer a specific research question or be of public benefit and are only approved if the information can be released in accordance with relevant secrecy provisions, and are in line with relevant legislations. For further information see ExternalRef removed.Informed consent was waived by the Australian Government Department of Human Services External Request Evaluation Committee, and this study and publication of subsequent results were approved by the Australian Government Department of Human Services External Request Evaluation Committee (RMS1280).
: Not applicable.
: MA is an employee of Janssen-Cilag Pty Ltd, the manufacturer of haloperidol, paliperidone and risperidone. SS is a former employee of Janssen-Cilag Pty Ltd. PJ and MHK are employees of Prospection Pty Ltd, the company contracted by Janssen-Cilag to undertake the analysis according to the protocol. NP reports speaker’s honoraria, advisory board participation, and conference expense reimbursement from Janssen-Cilag Pty Ltd in the six month period prior to submission of this paper. JM reports conference expense reimbursement from Janssen-Cilag Pty Ltd in the six month period prior to submission of this paper.